Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: A review and updated results of the Australian leukemia study group

Leukemia and Lymphoma

Volumn 28, Issue 3-4, 1998, Pages 315-327

  Bishop, James F ^a,c   Matthews, Jane P ^b   Young, Graham A R ^c   Bradstock, Kenneth ^d   Lowenthal, Raymond M ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d Westmont Hospital   (Australia)

^e ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Chemotherapy; Etoposide; High dose cytarabine; Intensified induction; VP 16

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUSTRALIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; DOSE RESPONSE; GASTROINTESTINAL TOXICITY; HUMAN; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SURVIVAL;

EID: 0031905441     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809092687     Document Type: Article

References (82)

1. Priesler, H., David, R. B., Kirshner, J. et al. (1987). Comparison of 3 remission induction regimens and two post-induction regimens for the treatment of acute non-lymphocytic leukemia. Blood, 69(5), 1441.
2. Wiernik, P. H., Banks, P. C., Case, D. C. et al. (1992). Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adults with acute myeloid leukemia. Blood, 79(2), 313.
3. Bishop, J. F., Lowenthal, R. M., Joshua, D. et al. (1990). Etoposide in acute non-lymphocytic leukemia. Blood, 75, 27.
4. Yates, J., Glidwell, O., Wiernik, P. et al. (1982). Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood, 60, 454-462.
5. Bishop, J. F., Matthews, J. P., Young, G. A. et al. (1996). A randomised study of high dose cytarabine in induction in acute myeloid leukemia. Blood, 87, 5.
6. Mayer, R. J., Davis, R. B., Schiffer, C. A. et al. (1994). Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med, 3331, 896-903.
7. Preisler, H. D. (1978). Failure of remission induction in acute myelocytic leukemia. Med Pediatr Oncol, 4, 278.
8. Ellison, R. R., Holland, J. F., Weil, M. et al. (1968). Arabinosylcytosine. A useful agent in the treatment of acute leukemia in adults. Blood, 32, 507-523.
9. Carey, R. W., Ribas-Mundo, M., Ellison, R. R. et al. (1975). Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia. Cancer, 36, 1560-1566.
10. Passe, S., Mike, V., Mertelsmann, R. et al. (1982). Acute nonlymphoblastic leukemia. Prognostic factors in adults with long-term follow up. Cancer, 50, 1462-1471.
11. Gale, R. P. and Cline, M. S. (1977). High remission induction rate in acute myeloid leukaemia. Lancet, 1, 497-499.
12. Mandelli, F., De Lipsis, E., Grignani, F. et al. (1978). Daunomycin, cytosine arabinoside and thioguanine (DAT) vs vincristine, cytosine arabinsode, and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocytic leukemia: a randomized collaborative study. Med Pediatr Oncol, 4, 231-240.
13. Wiernik, P. H., Glidwell, O. J., Hoagland, H. C. et al. (1979). A comparative trial of daunorubicin, cytosine arabinoside and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Med Pediatr Oncol, 6, 261-277.
14. Mayer, R. J. (1987). Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Sem Oncol, 14(4), 384-396.
15. Omura, G. A., Vogler, W. R., Lefante, J. et al. (1982). Treatment of acute myelogenous leukemia: Influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy. Cancer, 49, 1530-1536.
16. Preisler, H., David, R. B., Krishner, J. et al. (1987). Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute non-lymphocytic leukemia: A Cancer and Leukemia Group B Study. Blood, 69, 1441-1449.
17. Bishop, J. F. (1997). The treatment of adult acute myeloid leukemia. Semin Oncol, 22(1), 57-69.
18. Rai, K. R., Holland, J. F., Glidewell, O. J. et al. (1981). Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood, 58, 1203-1212.
19. Sauter, C., Berchtold, W., Foopp, M. et al. (1984). Acute myelogenous leukaemia: Maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet, 1, 379-382.
20. Vogler, W. R., Winton, E. F., Gordon, D. S. et al. (1984). A randomised comparison of post remission therapy in acute myelogenous leukemia: A Southeastern Cancer Study Group trial. Blood, 63, 1039-1045.
21. 2 in induction and maintenance therapy for acute myelocytic leukemia (AML). Proc Am Soc Clin Oncol, 6, 160 (abst 629).
22. Rees, J. K. H., Gray, R. G., Swinskey, D. et al. (1986). Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet, 2, 1236-1241.
23. Buchner, T., Hiddemann, W., Schaefer, U. W. et al. (1992). Combined effect of very early intensification and prolonged Post-remission chemotherapy in patients with AML. Leukemia, 6 (Suppl 4), 68-70.
24. 1. (9-acridinylamino methansesulphon-m-aniside (AMSA): a new effective drug in the treatment of adult acute leukemia. Ann Intern Med, 93, 17.
25. Louie, A. C. and Issell, B. F. (1985). Amsacrine (AMSA) - a clinical review. J Clin Oncol, 3, 562.
26. Paciucci, P. A., Ohnuma, T., Cuttner, J. et al. (1983). Mitoxantrone in patients with acute leukemia in relapse. Cancer Res, 43, 3919.
27. Estey, E. H., Keating, M. J., McCredie, et al. (1983). Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep, 67, 389.
28. Daghestani, A., Arlin, Z. A., Leyland-Jones, B. et al. (1985). Phase I and II clinical and pharmacological study of 4-methoxy daunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res, 45, 1408.
29. Carella, A. M., Santini, G., Martinengo, M. et al. (1985). 4-demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemia. Cancer, 55, 1452.
30. Clarkson, B. D., Gee, T., Mertelsmann, R. et al. (1986). Current status of treatment of acute leukemia in adults. An overview of the Memorial experience and review of the literature. Crit Rev Oncol/Hematol, 4, 221-248.
31. Arlin, Z. A., Case, D. C. Jr., Moore, J. et al. (1990). Randomised multicentre trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute non-lymphocytic leukemia (ANLL). Leukemia, 4, 177.
32. Martial, P., Ghilian, J. M., Ferrant, A. et al. (1990). High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukemia. Eur J Haematol, 45(3), 164-7.
33. Stuart-Harris, R., Simes, J., Coates, A. S. et al. (1987). Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone. Eur J Cancer Clin Oncol, 23, 557-561.
34. Supino, A., Necca, A., Dasidia, J. et al. (1977). Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res, 37, 4523.
35. Speth, P. A. J., Van de Loo, F. A. J., Linssen, P. C. M. et al. (1986). Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. Clin Pharmacol Ther, 40, 643.
36. Gillies, H. C., Herriot, D., Liang, R. et al. (1987). Pharmacokinetics of idarubicin (4-demethoxydaunorubicin IMI-30, NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol, 28, 303.
37. Hayat, M., Hurteloup, P., Parmeutier, C. et al. (1984). Phase I trial of idarubicin (4-demethoxydaunorubicin) in adult acute myeloid leukemia. Invest New Drugs, 2, 375.
38. Harousseau, J. L., Hurtleoup, P., Reiffers, J. et al. (1987). Idarubicin in the treatment of acute leukemia. (Exerpta Medica Pub., Amsterdam, The Netherlands), pp. 10.
39. Berman, E., Heller, G., Santorsa, J. et al. (1991). Results of a randomised trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinsode in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 77(8), 1666-1674.
40. Vogler, W. R., Velez-Garcia, E., Omura, G. et al. (1992). A phase 3 trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myeloeenous leukemia. J. Clin Oncol, 10(7), 1103-11.
41. Petti, M. C. and Mandelli, F. (1989). Idarubicin in acute leukemias: Experience of the Italian Cooperative Group GIMEMA. Semin Oncol, 16(1), 10-15 (Suppl 2).
42. Wheatley, K. (1995). Meta-analysis of randomised trials of idarubicin (IDAR) or mitoxantrone (MITO) vs daunorubicin as induction therapy for acute myeloid leukemia (AML). Blood, 86(10), 434a.
43. Leike, J. (1982). VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity. Cancer Chemother Pharmacol, 7, 103.
44. Rivera, G., Avery, T. and Roberts, D. (1975). Response to L1210 to combination of cytosine arabinoside and VM26 or VP16-213. Eur J Cancer, 11, 639.
45. Bishop, J. F. (1991). Etoposide in the management of acute leukemia: A review. Semin Oncol, 18 (Suppl 2), 62-69.
46. Van Echo, D. A., Lichenfeld, K. M. and Wiernik, P. H. (1977). Vinblastine, 5 azacytidine and VP16-213 therapy for previously treated patients with acute non-lymphocytic leukemia. Cancer Treat Rep, 61, 1599.
47. Dubowski, D., Kernoff, L. and Jacobs, P. (1978). Rapid remission induction in adult acute non-lymphocytic leukemia. Eur J Cancer, 14, 1177.
48. Letandre, L., Hinemann, V., Hoagland, C. H. et al. (1984). Phase I trial of VP16 and AMSA in combination in patients with refractory acute non-lymphocytic leukemia. Proc Amer Soc Clin Oncol, 3, 189.
49. Bishop, J. F., Joshua, D. E., Lowenthal, R. M. et al. (1986). A Phase I-II trial of cytosine arabinoside, daunorubicin and VP16-213 in adult patients with acute non-lymphocytic leukemia. Aust NZ J Med, 16, 48.
50. Parkiha, P., Powles, R., Treleaven, J. et al. (1990). High dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukemia: a single centre study. Br J Cancer, 62(5), 830-3.
51. Lowenthal, R. M., Matthews, J. P., Bishop, J. F. et al. (1993). Idarubicin, cytosine arabinoside in standard or high dose, and etoposide: combinations giving high remission rates in adult acute myeloid leukemia (AML). Blood, 82, 328a (abstract).
52. Vogler, W. R., McCarley, D. H., Stagg, M. et al. (1994). A Phase III trial of high dose cytosine arabinsode with or without etoposide in relapsed and refractory acute myelogenous leukemia. Leukemia, 9(11), 1847-53.
53. Burnett, A. K., Goldstone, A. H., Stevens, R. et al. (1995). The value of bone marrow transplantation in AML CRI in intensively treated patients. The MRC AML 10 trial. Ann Hematol, 70 (Suppl 1), A112.
54. Slevin, M. L., Clark, P. I., Joel, S. P. et al. (1989). A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol, 7(9), 1333,40
55. 1 - triphosphate in leukemic blasts during treatment of refactory leukemia with high dose 1-β-D arabinofuranosylcytosine. Scand J Haematol, 44, 51-59.
56. 1 - triphosphate and response to therapy. Cancer Res, 39, 42-49.
57. Hines, J. D., Oken, M. M., Mazza, J. et al. (1984). High dose cytarabine and m-AMSA is effective therapy in relapse acute non-lymphocytic leukemia. J Clin Oncol, 2 (suppl 1), 545-549.
58. Champlin, R., Ho, W., Winston, D. et al. (1987). Treatment of adults with acute myelogenous leukemia: prospective evaluation of high dose cytarabine in consolidation chemotherapy and with bone marrow transplantation. Semin Oncol, 14, 1-6.
59. Mayer, R. J., Schiffer, C. A., Peterson, B. A. et al. (1987). Intensive post-remission therapy in adults with acute non-lymphocytic leukemia using various dose schedules of ara-C: a progress report from CALGB. Semin Oncol, 14 (2 suppl 1), 25-31.
60. Brito-Babapulle, F., Catovsky, D., Newland, A. C. et al. (1987). Treatment of acute myeloid leukemia with intermediate dose cytarabine and mitoxantrone. Semin Oncol, 14(2 supp 1), 51-52.
61. Bishop, J. F., Matthews, J. P., Young, G. A. et al. (1994). The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukaemia. Leukaemia and Lymphoma, 15, 79-84.
62. Hryniuk, W. and Bush, H. (1984). The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol, 2, 1281-1288.
63. Williams, S. D., Birch, R., Einhorn, L. H. et al. (1987). Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med, 316, 1435-40.
64. Fisher, R. I., Gaynor, E., Dahlberg, S. et al. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med, 328, 1002-6.
65. Rubin, E. H., Anderson, J. W., Berg, D. T. et al. (1992). Risk factors for high dose cytarabine neurotoxicity: an analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia. J Clin Oncol, 10(6), 948-53.
66. Weick, J. K., Kopecky, K. J., Appelbaum, F. R. et al. (1996). A randomised investigation of high dose versus standard dose cytoside arabinoside with daunorubicin in patients with previously untreated acute myelogenous leukemia. Blood, 88, 2841-2851.
67. Plunkett, W., Liliemark, J. O., Estey, E. et al. (1987). Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Semin Oncol, 14(2 Suppl 1), 159-166.
68. Mayer, R. J., Weinstein, H. J., Coral, F. S. et al. (1982). The role of intensive post induction chemotherapy in the management of patients with acute myelogenous leukemia. Cancer Treat Rep, 66, 1455-1462.
69. Embury, S. H., Elias, L., Heller, P. H. et al. (1977). Remission maintenance therapy in acute myelogenous leukemia. West J Med, 126, 267-272.
70. Cassileth, P., Harrington, D., Hines, J. et al. (1986). Maintenance therapy in adult acute nonlymphocytic leukemia (ANLL) prolongs initial complete remission duration (CRDUR). Blood, 68, 220a, (suppl 1, abstrc 758).
71. Cassileth, P. A., Begg, C. B., Bennett, J. M. et al. (1984). A randomised study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood, 63, 843-847
72. Dutcher, J. P., Wiernik, P. H., Markus, S. et al (1988). Intensive maintenance therapy improves survival in adult acute non-lymphocytic leukemia: an eight year follow up. Leukemia, 7, 413.
73. Casseleith, P. A., Begg, C. B., Silber, R. et al. (1987). Prolonged unmaintained remission after intensive consolidation therapy in adult acute non-lymphocytic leukemia. Cancer Treat Rep, 71, 137.
74. Preisler, H. D., Raza, A., Early, A. et al. (1987). Intensive remission consolidation therapy in the treatment of acute non-lymphocytic leukemia. J Clin Oncol, 5, 722-30.
75. Tricot, G., Boogaerts, M. A., Vlientink, R. et al. (1987), The role of intensive remission induction and consolidation treatment in patients with acute myeloid leukemia. Brit J Haematol, 66, 37-44.
76. Wolff, S. N., Herzig, R. H., Fay, J. W. et al. (1989). High dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long term follow up and results. J Clin Oncol, 7, 1260-7.
77. Schiller, G., Gajewski, J., Territo, M. et al (1992). Long term outcome of high dose cytarabine based consolidation therapy for adults with acute myelogenous leukemia. Blood, 80, 2977-82.
78. Cassileth, P. A., Lynch, E., Hines, J. D. et al. (1992). Varying intensity of post-remission therapy in acute myeloid leukemia. Blood, 79(8), 1924-1930.
79. Lowenthal, R. M., Bradstock, K. M., Matthews, J. P. et al. (1995). Idarubicin, cytarabine in standard dose or high dose and etoposide ± lenograstim (G-CSF) for adult acute lyeloid leukaemia (AML). Blood, 86 (10), 768a, (abstract).
80. Clift, R. A., Buckner, C. D., Thomas, E. D. et al. (1987). The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant, 2, 243-248.
81. Bishop, J. F. (1994). Intensified therapy for acute myeloid leukemia. N Engl J Med, 331, 941-942, (editorial).
82. Bishop, J. F., Matthews, J. P., Young, G. A. R. and Bradstock, K. M. (1996). Factors associated with poor outcome following induction therapy for acute myeloid leukemia. Int J Hematol, 64 (suppl 1), S19.